Abstract
A subset of tyrosine kinases are activated by mutations which contribute to the malignant transformation, growth, and metastasis of human cancers. Mutations change the expression, conformation and/or stability of tyrosine kinases, often leading to constitutive activation of the signaling pathways the kinases regulate. Given that tyrosine kinases are key members of signaling cascades, mutations have multiple effects on various cellular proteins. This review will focus on four kinases (EGFR, c-Met, c-Kit, and PI3-kinase) known to be mutated in human cancer. It will discuss the effects that these mutations have on the biology of tumors, and how our understanding of the structure and function of kinases and their mutations is currently being used to design targeted treatments.
Keywords: Mutation, EGFR, PI3-kinase, c-Met, tyrosine kinase, NSCLC, ovarian cancer
Current Molecular Medicine
Title: Tyrosine Kinase Mutations in Human Cancer
Volume: 7 Issue: 1
Author(s): Ernst Lengyel, Kenjiro Sawada and Ravi Salgia
Affiliation:
Keywords: Mutation, EGFR, PI3-kinase, c-Met, tyrosine kinase, NSCLC, ovarian cancer
Abstract: A subset of tyrosine kinases are activated by mutations which contribute to the malignant transformation, growth, and metastasis of human cancers. Mutations change the expression, conformation and/or stability of tyrosine kinases, often leading to constitutive activation of the signaling pathways the kinases regulate. Given that tyrosine kinases are key members of signaling cascades, mutations have multiple effects on various cellular proteins. This review will focus on four kinases (EGFR, c-Met, c-Kit, and PI3-kinase) known to be mutated in human cancer. It will discuss the effects that these mutations have on the biology of tumors, and how our understanding of the structure and function of kinases and their mutations is currently being used to design targeted treatments.
Export Options
About this article
Cite this article as:
Lengyel Ernst, Sawada Kenjiro and Salgia Ravi, Tyrosine Kinase Mutations in Human Cancer, Current Molecular Medicine 2007; 7 (1) . https://dx.doi.org/10.2174/156652407779940486
DOI https://dx.doi.org/10.2174/156652407779940486 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis, Antioxidant and Anticancer Activity of New Coumarin Derivatives Linked with Thiazole, Isoxazole or Pyrazole Moiety
Letters in Drug Design & Discovery Synthesis, Cytotoxic and Heparanase Inhibition Studies of 5-oxo-1-arylpyrrolidine-3- carboxamides of Hydrazides and 4-amino-5-aryl-4H-1,2,4-triazole-3-thiol
Current Organic Synthesis Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Current Cancer Drug Targets Recent Patents in Oncolytic Virotherapy
Recent Patents on Biotechnology Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies HSP60 as a Drug Target
Current Pharmaceutical Design Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry Kinase Inhibitors in Multitargeted Cancer Therapy
Current Medicinal Chemistry Concanavalin A, from an Old Protein to Novel Candidate Anti-Neoplastic Drug
Current Molecular Pharmacology Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design The Epigenetic Origin of Aneuploidy
Current Genomics EBV-Related Malignancies, Outcomes and Novel Prevention Strategies
Infectious Disorders - Drug Targets Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
Current Gene Therapy Connecting A Tumor to the Environment
Current Pharmaceutical Design Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Novel Drugs Targeting Microtubules: the Role of Epothilones
Current Pharmaceutical Design